Top Injectable Manufacturer in Djibouti – Reliable Pharmaceutical Solutions
Top Injectable Manufacturer in Djibouti – Reliable Pharmaceutical Solutions
Last Updated: September 10, 2026
TL;DR: Djibouti publishes no list of foreign regulators it trusts. Its 1991 medicines law applies a country-of-origin test instead: an imported speciality may be registered only if it is already registered where it was made. That is unusually open to an Indian manufacturer — but the Ministry of Health's own strategy records that the registration system is not operated, so the gates that bind are the import visa, the pharmacist monopoly on importing, and CAMME's tenders.
Key Takeaways
Djibouti's Law 145/AN/91 requires an imported speciality to be registered in its country of origin; no foreign agency is named, so India is neither listed nor excluded.
The Ministry of Health's supply strategy, adopted by Law 14/AN/23 of 10 March 2024, states that the registration system is not applied — the control point in practice is the import visa.
Only pharmacists may import and wholesale medicines, so a foreign manufacturer cannot import in its own name and must work through a licensed local establishment.
Djibouti participates in IGAD's medicines-harmonisation initiative, whose secretariat sits in Djibouti City and which shares joint WHO cGMP inspections between seven regulators.
Introduction: What an Injectable Manufacturer in Djibouti Has to Prove
This series usually opens by asking whether a country recognises the Indian regulator. Djibouti answers differently: it publishes no list of foreign agencies at all. Article 8 of Law 145/AN/91 of 10 February 1991 says instead that imported specialities may be registered only if they have already been registered in their country of origin, and Article 88 of Law 48/AN/99 makes the parallel demand of generics — that they be legally marketed in the producing country. The test is about where a product comes from, not about who approved it.
For a Gujarat manufacturer that framing is structurally favourable: there is no list to get onto and none to be excluded from, and the burden is purely evidentiary. Djibouti is also a listed participant in the WHO Certification Scheme, which makes a WHO-format Certificate of a Pharmaceutical Product the recognised instrument for carrying that proof. But the openness has a counterpart that any serious supplier should understand before quoting: the register this law describes is, on the Ministry of Health's own account, not currently being operated.
What Sets a World-Class Injectable Manufacturer in Djibouti Apart
The Ministry's pharmaceutical supply strategy, adopted by Law 14/AN/23 of 10 March 2024, states plainly that the registration system run by the medicines directorate is not applied, and its action plan lists drafting the medicines-registration regulation as the first activity to complete. We could not find an implementing decree for the 1991 law's procedural articles, and we found no published fee schedule and no published timeline anywhere. Where a market's own sources leave those numbers unstated, we print neither and confirm both with the directorate.
So the constraint that actually binds sits elsewhere, and it sits on the importer rather than on the factory. Article 2 of the 1991 law reserves the import, wholesale and supply of medicines to pharmacists, and Article 4 adds a nationality-or-reciprocity condition together with registration on the professional roll. A 2024 ministerial decree sets out the sequence an establishment must follow — approval, provisional authorisation, an inspection of conformity, then definitive authorisation, with annual re-inspection. The consequence is unambiguous: Farbe Firma cannot import into Djibouti in its own name, and the quality of a Djiboutian partner is the licence itself, not a commercial detail. We should also flag what we could not establish: no decree we found specifies whether the manufacturer or the local agent owns a Djiboutian marketing authorisation, and that question should be put to the directorate rather than assumed.
Quality Systems Behind Every Sterile Injectable We Ship to Djibouti
Because the country-of-origin test asks what the product is at home rather than who signed off abroad, the dossier has to carry its own weight. Every batch Farbe Firma releases is manufactured under WHO-GMP certification in ISO Class 5 filling environments, with terminal sterilisation or validated aseptic processing, media fills and environmental monitoring. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised presentations. Stability runs on ICH Q1A protocols with Q1B photostability, on the climatic zone appropriate to a Red Sea port rather than a temperate default.
Documentation is assembled in CTD format, with ACTD available where a buyer's regulator prefers it, so one dossier can serve a Djiboutian filing, a regional submission and a donor qualification. That matters more here than in most markets: Djibouti has no national quality-control laboratory and no national pharmacovigilance centre, and its own strategy records that it is not a member of the WHO Programme for International Drug Monitoring. The manufacturer's own quality system is therefore doing work a domestic laboratory does elsewhere.
Planning a shipment into Djibouti or onward to the Horn of Africa? Talk to our export team about dossier formats, CoPP issuance and cold-chain routing through the Port of Djibouti.
Why Farbe Firma is the Trusted Injectable Manufacturer in Djibouti for Global Buyers
Djibouti is a small market attached to a very large corridor, and the two need separate answers. Domestically the numbers are modest: the World Bank puts the population at 1,168,722 in 2024, current health expenditure at 2.28% of GDP in 2023, with 28.84% paid out of pocket and 23.60% financed externally. Public purchasing runs largely through CAMME, the central medical stores, whose 2025 forecast budget, set out in a 2024 ministerial order, shows a medicines-sales line of 395,000,000 Djiboutian francs. We could not reconcile that line with the 1.48 billion franc medicines purchase budget reported for 2020 in the Ministry's own strategy; the two published figures conflict, and we print both rather than choosing.
The corridor is the other half of the picture. Djibouti's port handles the overwhelming majority of landlocked Ethiopia's trade, and transit clears under a regime distinct from domestic entry: medicines entering Djibouti's own market require the Ministry of Health's visa, while goods bound onward answer to the destination regulator. For that flow the authority that matters is Ethiopia's EFDA, which WHO lists at maturity level 3 for medicines. This corrects a common assumption — India's CDSCO does appear on WHO's maturity-level listing, but the scope column reads vaccines only, so it is not a medicines credential in any market that reads that list carefully.
Finally, the regional route is real, and it is administered from Djibouti City. Djibouti is one of seven regulators in IGAD's medicines-harmonisation work, which accepts dossiers in ICH CTD format, shares joint WHO cGMP site inspections between members for reliance purposes, and asks applicants to commit to marketing in at least two member states. IGAD recommends rather than approves — each authority still issues its own marketing authorisation — and IGAD itself labels its published timelines indicative. Farbe Firma's range maps closely onto the initiative's priority list, which includes oxytocin, magnesium sulphate, tranexamic acid and fixed-dose antimicrobials. Djibouti has neither signed nor ratified the African Medicines Agency treaty, so AMA is not a route here today.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Does Djibouti recognise Indian regulatory approvals such as CDSCO?
Not in those terms. We found no list of recognised foreign agencies in Djiboutian law. The 1991 law requires that an imported speciality already be registered in its country of origin, which an Indian registration satisfies on its face. India is neither named nor excluded: the test is about origin, not about the approving agency.
Is the Indian Pharmacopoeia accepted in Djibouti?
We cannot say, in either direction. Djiboutian law provides for a ministerial order listing the pharmacopoeias that may be referenced and prohibits reference to any other. We were unable to locate that order, so whether the Indian Pharmacopoeia appears on it is unknown to us. Farbe Firma releases to USP, BP, IP or EP as a buyer requires.
Can Farbe Firma import into Djibouti directly?
No. Djiboutian law reserves the import, wholesale and supply of medicines to pharmacists, with a nationality-or-reciprocity condition and registration on the professional roll, and a 2024 decree sets out the approval and inspection sequence an establishment must complete. A foreign manufacturer supplies through a licensed local establishment or to CAMME, not in its own name.
What does registration in Djibouti cost, and how long does it take?
We are not going to print a number for either. No fee schedule and no statutory timeline were found in any published Djiboutian instrument we could read, and the Ministry's own strategy records that the registration regulation is still to be drafted. Both should be confirmed with the medicines directorate before a launch plan depends on them.
Does Farbe Firma supply the Ethiopia transit corridor through Djibouti?
Yes, and the two flows are worth separating. Goods entering Djibouti's domestic market need the Ministry of Health's import visa; goods in transit to Ethiopia answer to Ethiopia's EFDA, which WHO lists at maturity level 3 for medicines. Because both countries participate in IGAD, a single CTD dossier and a shared cGMP inspection can serve both ends of the corridor.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Farbe Firma Pvt Ltd — WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Exporting to 30+ countries. Email: director@farbefirma.org | Request a Quote / View Products / FAQ / Blog
Comments